Inherited germline mutations in a single copy of the BRCA2 tumorsuppressor gene predispose to breast, ovarian, pancreatic and other cancers 1 . Somatic loss of the second allele may occur in tumors that develop in mutation carriers 2, 3 , as with other tumor-suppressor genes 4 , but loss of this second allele is not always essential for tumorigenesis 5 . Much evidence has suggested that BRCA2 exerts its tumor-suppressive function in the cell nucleus through its role in the repair of DNA breaks by homologous recombination (HR) 6, 7 . BRCA2 controls the accumulation of the RAD51 recombinase enzyme at sites of DNA breakage in the nucleus 8, 9 , nucleates RAD51 filament formation at single-stranded DNA (ssDNA)-double-stranded DNA (dsDNA) junctions 10 and promotes RAD51 binding on ssDNA while inhibiting dsDNA binding [11] [12] [13] [14] [15] . However, defective HR typically occurs in cells lacking both BRCA2 alleles 7 , and so it remains unclear how heterozygous cancer-associated mutations may compromise the function of BRCA2.
Inherited germline mutations in a single copy of the BRCA2 tumorsuppressor gene predispose to breast, ovarian, pancreatic and other cancers 1 . Somatic loss of the second allele may occur in tumors that develop in mutation carriers 2, 3 , as with other tumor-suppressor genes 4 , but loss of this second allele is not always essential for tumorigenesis 5 . Much evidence has suggested that BRCA2 exerts its tumor-suppressive function in the cell nucleus through its role in the repair of DNA breaks by homologous recombination (HR) 6, 7 . BRCA2 controls the accumulation of the RAD51 recombinase enzyme at sites of DNA breakage in the nucleus 8, 9 , nucleates RAD51 filament formation at single-stranded DNA (ssDNA)-double-stranded DNA (dsDNA) junctions 10 and promotes RAD51 binding on ssDNA while inhibiting dsDNA binding [11] [12] [13] [14] [15] . However, defective HR typically occurs in cells lacking both BRCA2 alleles 7 , and so it remains unclear how heterozygous cancer-associated mutations may compromise the function of BRCA2.
To address this issue, we investigated the cellular effects of a common cancer-associated BRCA2 missense mutation (BRCA2 D2723H ) in which Asp2723 is replaced by histidine 16 . Remarkably, our studies reveal an unreported mechanism wherein the localization of BRCA2 and RAD51 to the cell nucleus is governed by the masking of NESs by protein-protein interactions. The BRCA2 D2723H mutant impairs this mechanism, triggering decreased nuclear accumulation of RAD51 even when wild-type (WT) BRCA2 is also present, which contributes to its deleterious effects in the heterozygous state. Thus, our results link the nucleocytoplasmic translocation of the BRCA2 tumor suppressor to the cellular mechanisms of disease after its germline inactivation.
RESULTS

DSS1 binding to BRCA2 is critical for nuclear localization
Cancer-associated missense mutations in human BRCA2 occur frequently in the region that spans residues ~2500-2850 (ref. 17), which mediates the interaction (Supplementary Fig. 1a ) of BRCA2 with the small (70-residue), acidic protein DSS1 (refs. 18,19) . One of these mutations, BRCA2 D2723H , which alters a single aspartic acid residue at position 2723 in the 3418-residue BRCA2 protein to histidine, has been reported >30 times in the Breast Cancer Information Core database (http://research.nhgri.nih.gov/bic/). Evidence from linkage analysis of human kindreds 16 and functional studies on mouse embryonic stem (ES) cells has suggested that the inheritance of BRCA2 D2723H is functionally deleterious 20 . Because the BRCA2 D2723H mutation affects a key conserved residue (Supplementary Fig. 1a ) that directly contacts DSS1 (ref. 19 ), we first determined whether it affects the BRCA2-DSS1 interaction. We generated a fragment of BRCA2 spanning the entire DSS1-binding domain (DBD) across residues 2461-2975 fused to 'super' YFP (sYFP) plus a nuclear localization signal (NLS) and coexpressed it in human 293T cells with an mCherry-tagged form of full-length DSS1. The sYFP-DBD fragment is >70 kDa long and therefore requires a heterologous NLS to induce nuclear localization. Although the WT form of NLS-sYFP-DBD coimmunoprecipitated with mCherry-DSS1 (Fig. 1a) , the BRCA2 D2723H mutant did not, despite having higher expression levels. Similarly, a mutant form of the DBD (BRCA2 W2725A ) in which an evolutionarily conserved tryptophan residue at position 2725 that has been implicated in DSS1 binding 21 is altered to alanine immunoprecipitated poorly with mCherry-DSS1. Supplementary Fig. 1b) , a near-field coupling effect, reports on specific intermolecular interactions when the interacting fluorophores are less than ~5 nm apart 22 . sYFP and mCherry are an optimized FRET pair, with a Förster radius of >5 nm, and thus exhibit an enhanced FRET efficiency compared to traditional blue-shifted fluorophore pairs 23 . We used fluorescence lifetime imaging microscopy (FLIM) to measure FRET on the donor sYFP molecule, which has a fluorescence lifetime that shows monoexponential decay 23 ( Supplementary Fig. 1c ). Co-transfection of mCherry-DSS1 with NLS-sYFP-DBD caused a significant decrease in the lifetime of sYFP from 3,100 to 2,750 ps on average, as evidenced by time-correlated single photon counting (TCSPC), which is suggestive of FRET through the direct interaction of these molecules ( Fig. 1b and Supplementary Fig. 1d ). In contrast, the lifetime of the NLS-sYFP-tagged BRCA2 D2723H and BRCA2 W2725A mutants remained close to 3,000 ps, confirming that the mutations inhibit the interaction of the BRCA2 DBD with DSS1 directly (Fig. 1b) . Human BRCA2 normally localizes to the cell nucleus through tandem nuclear localization signals (NLSs) at its extreme C terminus 24 . In contrast, full-length BRCA2 harboring the D2723H mutation mislocalized predominantly to the cytoplasm in transfected cells (Fig. 1c) , as has been shown previously 20, 25 . Notably, BRCA2 W2725A similarly mislocalized (Fig. 1c) , suggesting a correlation between the loss of DSS1 binding and cytoplasmic mislocalization.
DSS1 masks a nuclear exclusion sequence in BRCA2
Neither the D2723H nor the W2725A mutation is predicted to alter the canonical NLSs positioned in exon 27 of BRCA2 (ref. 24) . This prompted us to survey BRCA2 for NESs using the NetNES algorithm, which employs neural networks to predict consensus motifs fitting the pattern φX 1-3 φX 1-3 φXφ, where φ is a hydrophobic amino acid (methionine, phenylalanine, isoleucine, valine or leucine) and X is any amino acid 26 . We detected four such potential NES motifs in the DSS1-binding region of BRCA2 (Supplementary Fig. 2a ). One motif (residues 2682-2698, encoded in exon 18 of BRCA2) showed strong evolutionary conservation, particularly of the critical hydrophobic residues (Fig. 2a) . When fused to sYFP, this motif induced nuclear exclusion, which is in contrast to the effects of a control BRCA2-derived peptide of similar size (Fig. 2b) ; these results substantiate the NES function of the motif.
The cytoplasmic mislocalization of BRCA2 mutants carrying alterations that affect DSS1 binding, but not intrinsic NLS or NES motifs, raises the possibility that the BRCA2-DSS1 interaction masks an NES of BRCA2. Consistent with this idea, the structure of the BRCA2-DSS1 complex 19 suggests that the residues that are critical for binding to exportins in the potential NES spanning residues 2682-2698 in BRCA2 are obscured by DSS1 (Fig. 2c) . Moreover, overexpression of DSS1 in cells expressing WT forms of either NLS-sYFP-DBD or full-length BRCA2 enhanced nuclear localization, whereas the BRCA2 D2723H and BRCA2 W2725A mutants were not similarly affected ( Supplementary Fig. 2b-d ). Together these findings support a model wherein the binding of DSS1 to BRCA2 is essential for its nuclear retention through the masking of an NES within the DBD.
BRCA2 masks a nuclear exclusion sequence in RAD51
The RAD51 recombinase, a 37-kDa protein that is central to DNA repair by HR 27 , binds directly to the BRC repeats of BRCA2 (refs. 6,28) , creating an interaction that is essential for the efficient completion of recombination reactions [10] [11] [12] [13] [14] . Eight BRC repeats are present in human BRCA2, and the structural basis of their interaction with RAD51 has been characterized by crystallography and structurefunction analyses in mammalian cells 28, 29 . Notably, a NetNES analysis of human RAD51 identified a putative NES spanning residues 245-260 (Fig. 3a) that is strongly conserved across species (Fig. 3b) . This NES lies within a recently identified binding site for the BRC repeats of BRCA2 (ref. 29) , and an examination of the crystal structure revealed that key exportin-binding residues within this RAD51 NES are probably masked when the protein is bound to BRCA2 (Fig. 3c) . The RAD51 NES was sufficient to exclude sYFP from the nucleus when fused to the fluorophore (Fig. 3d) . Mutation of the residues Ser208 and Ala209 in RAD51 has been reported to abolish its binding to the BRC repeats in BRCA2 but not its ability to oligomerize 30 . Anti-BRCA2   W  2 7 2 5 A  W  2 7 2 5 A  D  2 7 2 3 H  D  2 7 2 
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This mutant localized to the cytoplasm when expressed in DT40 cells lacking endogenous RAD51 (Fig. 3e) . These observations not only confirm that the nuclear retention of RAD51 requires binding to BRCA2 but also corroborate that a RAD51 NES is masked by interaction with the BRC repeats of BRCA2.
In vitro interaction of CRM1 with NESs in BRCA2 and RAD51
We demonstrated that putative NESs identified in the DSS1-binding domain of BRCA2 and the BRCA2-binding region of RAD51 share the expected consensus characteristics and can direct the nuclear exclusion of sYFP when fused to this heterologous protein. However, leucine residues in NES-like motifs frequently contribute to the buried hydrophobic cores of protein folds and may therefore be inaccessible for interaction with the nuclear exportin CRM1 in their native context 31, 32 . To address this issue, we tested the ability of glutathione S-transferase (GST)-tagged forms of the NES-containing domains of BRCA2 and RAD51 to bind in vitro to recombinant CRM1 in the presence of an active GTP-bound Q69L form of the essential cofactor Ran under the experimental conditions described previously 33 . We found that a GST-tagged recombinant protein encoding the DBD region of BRCA2 bound to recombinant CRM1 in the presence of a c (Fig. 4a, lane 3) , whereas GST alone did not (Fig. 4a,  lane 1) . Moreover, the addition of DSS1 inhibited this interaction (Fig. 4a , lane 4) in a dose-dependent manner (Fig. 4b) . These results prompted us to test the effect of the D2723H mutation, which is expected to prevent DSS1 binding. Indeed, the D2723H mutant form of the BRCA2 DBD interacted constitutively with CRM1 regardless of whether DSS1 was present (Fig. 4a , lanes 5 and 6). Thus, our findings provide biochemical evidence that the DBD region of BRCA2 contains authentic NES motifs that are capable of binding CRM1, that this interaction is lost when the NESs are masked by the binding of DSS1 and that loss of this interaction in the BRCA2 D2723H mutant promotes constitutive CRM1 binding, which is consistent with the nuclear export and cytoplasmic mislocalization of the mutant protein.
In addition, we found biochemical evidence that RAD51 contains CRM1-binding NESs that are masked by interaction with the BRC4 region of BRCA2. In these experiments, we used the F86E form of RAD51, which we characterized previously 28, 30 , to enable its purification without the spontaneous in vitro aggregation that is typical of recombinant WT RAD51 (refs. 28,34) . A GST-tagged version of this protein bound to CRM1 in the presence of Ran-GTP (Fig. 4c) . The addition of the BRC4 region of BRCA2 prevented CRM1 binding (Fig. 4c , compare lanes 3 and 4) in a dose-dependent manner (Fig. 4d) . Notably, a mutant form of RAD51 (SAM208-210LEA, denoted here RAD51-SAM), which we have previously shown 28, 30 to be incapable of BRC4 binding, interacted constitutively with CRM1 regardless of whether BRC4 was present ( 4) and GST-RAD51-SAM (lanes 5 and 6) immobilized on a glutathione-Sepharose matrix in the absence (lanes 3 and 5) or presence of (lanes 4 and 6) of BRC4 peptide at a six-fold molar excess. (d) Representative titration (of three total replicates) with GST as a specificity control, from which the molar excess of BRC4 peptide used in c was optimized. Proteins were visualized with antibodies to histidine or GST. CRM1 protein was tagged with histidine (uncropped blots are shown in Supplementary Fig. 8 ). npg a r t i c l e s results recapitulating exportin-cargo interactions using recombinant proteins provided strong biochemical evidence for a model wherein CRM1-dependent nuclear export-and its masking by proteinprotein interactions-is a critical determinant of BRCA2 and RAD51 localization. Our attempt at en bloc replacement of consensus hydrophobic residues within the proposed NESs (by substitution with alanine of Leu2686, Leu2688, Leu2696 and Ile2694 in the BRCA2 stretch from residues 2682-2698 and of Leu245, Leu249, Leu253 and Leu255 in the RAD51 stretch from residues 245-260) was beyond the scope of this work, as the BRCA2 and RAD51 domains encoding the putative NESs exhibited poor yield and solubility in bacterial expression. Moreover, further mutational analysis of the contributions made by residues located outside these motifs is difficult because the exact length and nature of the NES sequences that are required for CRM1 binding have been reported to be variable 33, 35 , as are the potential binding modes between CRM1 and its various substrates 36 . Future structural work will be required to precisely define the residues contributing to NES activity.
A heterozygous D2723H mutation in BRCA2 mislocalizes RAD51 Our findings suggest that the nuclear retention of BRCA2 and RAD51 depends on NES-masking interactions between BRCA2 and DSS1 and between BRCA2 and RAD51. To investigate whether these interactions are interdependent, we first tested the effect of BRCA2 depletion on RAD51 localization using RNA interference (Fig. 5a) . We used an automated microscopic assay in which the nucleocytoplasmic difference is calculated by subtracting the amount of RAD51 in a cytoplasmic ring surrounding the nucleus from the amount of RAD51 in a circular area within the nuclear boundary (as defined by DNA staining) (Fig. 5a, inset) . We found that depletion of BRCA2 by RNA interference decreased the nuclear localization of RAD51 ( Fig. 5a and Supplementary Fig. 3a-c) , which is consistent with a role for BRCA2 in the nuclear retention of RAD51.
Because humans who inherit the D2723H mutation on a single allele of BRCA2 are predisposed to cancer, this raises the possibility that the mutant protein exerts a trans-dominant effect on RAD51 localization when in the heterozygous state. Accordingly, we examined RAD51 localization in mouse ES cells engineered to be heterozygous for the human BRCA2 D2723H mutant in comparison to an appropriate WT control in an identical genetic background 20 . In this system, one allele of mouse (mm) Brca2 was disrupted by gene targeting, and the cells were complemented with a bacterial artificial chromosome (BAC) containing a segment of human chromosome 13 encoding human (hs) BRCA2. This BAC has been reported to drive near-endogenous expression of BRCA2 and is sufficient to replace mmBrca2 function in these cells, as evidenced by the rescue of lethality when the second endogenous mmBrca2 allele is also disrupted 20 . The total levels of BRCA2 and RAD51 expression were comparable in ES cells expressing either WT BRCA2 or BRCA2 D2723H (Supplementary Fig. 4a,b) . We examined the distribution of RAD51 in these cells by biochemical fractionation and quantitative western blotting (Fig. 5b) because of technical difficulties in performing accurate microscopic analyses of protein localization in the ES cells. We observed an increase in the amount of cytoplasmic RAD51 in cells carrying a single allele of BRCA2 D2723H , with a corresponding decrease in the nuclear levels of the protein (Fig. 5b,c) both in the absence (Fig. 5d) and presence (Fig. 5e ) of DNA damage induced by mitomycin C (MMC). Mutant BRCA2 D2723H expressed from the BAC in these cells was also predominantly cytoplasmic, unlike WT BRCA2 (ref. 20) (Fig. 5d,e) . 
r t i c l e s
Together these findings suggest a mechanism underlying the deleterious effects of the BRCA2 D2723H mutant when present in the heterozygous state and coexpressed with WT BRCA2.
BRCA2 and DSS1 promote RAD51 nuclear enrichment
There is evidence that RAD51 is enriched in the nucleus during the response to genotoxic lesions that are repaired by HR 37, 38 . We characterized this effect further by analyzing the nucleocytoplasmic distribution of RAD51 after DNA damage in human cells using automated microscopy. Exposure to the DNA-damaging agents etoposide and MMC caused an increase in the relative amount of nuclear RAD51, as evidenced by changes in the nuclear-cytoplasmic difference of the average pixel intensities within the two regions ( Fig. 6a and Supplementary Fig. 5 ). Moreover, genotoxins (e.g., MMC, carboplatin, the poly-(ADP-ribose) polymerase (PARP) inhibitor KU-0058948, hydroxyurea or aphidicolin) generating DNA lesions that are known to engage pathways for repair by HR enhanced the nuclear enrichment of RAD51 to a greater degree than other genotoxins (Fig. 6b) . Depletion of ataxia telangiectasia mutated (ATM), ATM and Rad53 related (ATR) or CHK1, which are damage-response kinases 39 , diminished the nuclear enrichment of RAD51 after MMC exposure, confirming that this response depends on the cellular pathways that sense and signal DNA damage ( Fig. 6c and Supplementary  Fig. 6 ). Notably, depletion of BRCA2 or DSS1 also affected the nuclear enrichment of RAD51 after genotoxic stress ( Fig. 6d and Supplementary Fig. 6 ). Using Flag-BRCA2-complemented EUFA423 cells (Supplementary Fig. 7 ), we showed that DNA damage also increases the levels of nuclear BRCA2, as measured with the Cellomics ArrayScan (Supplementary Fig. 7c ), and depletion of DSS1 causes a decrease in nuclear Flag-BRCA2 levels ( Supplementary  Fig. 7d ). Collectively these results suggest that the enhanced nuclear distribution of RAD51 is a DNA-damage response that is dependent on BRCA2 and DSS1 and that may be compromised by cancer-associated mutations that disrupt the DSS1-BRCA2 interaction.
DISCUSSION
The findings we report here suggest a new mechanism controlling the intracellular distribution of the RAD51 recombinase (Fig. 7) wherein NESs present in BRCA2 and its cargo, RAD51, must be masked by complex formation between BRCA2, DSS1 and RAD51 in order to permit nuclear localization. The NES-masking mechanism suggested by our findings reveals an additional layer of regulation that has not been recognized in earlier work reporting that RAD51 enters the nucleus only when bound to a partner, RAD51C 38 , which contains an NLS. The location of the proposed NESs near the hydrophobic protein cores (Figs. 2c and 3c) raises the possibility that these motifs are exposed for CRM1 binding by unfolding in the absence of the masking partner protein, suggesting a mechanism to ensure that only functional BRCA2-DSS1-RAD51 complexes are retained in the nucleus. Moreover, RAD51 oligomerization also probably regulates its nuclear localization. Both in vitro and in vivo 30, 34 , an equilibrium is believed to exist between RAD51 monomers and oligomers of varying stoichiometries whose abundances are closely regulated by interaction with factors such as RAD52 or the BRC repeats of BRCA2 (refs. 30,40) . Although RAD51 monomers (37 kDa) may pass freely into the nucleus, RAD51 oligomers (≥74 kDa) probably do not equilibrate passively across nuclear pores, which generally accommodate substrates ≤60 kDa (reviewed in ref. 41 ). There is structural 28 , biochemical 34 and cell-biological 28, 30 evidence that RAD51 oligomerization is suppressed by its interaction with the BRC repeats of BRCA2. This may help create a pool of monomeric RAD51 in the cytoplasm for transport into the nucleus through free nuclear pore entry or for binding to partner proteins (including RAD51C) that contain NLSs. The RAD51 monomer-oligomer equilibrium could also exist within the nucleus but is probably biased toward DNA-bound oligomers or a b c Figure 7 A hypothetical model for BRCA2 and RAD51 nuclear localization through masking of NESs. (a) The proposed mechanism wherein the nuclear retention of BRCA2 (red oblong shape) is allowed when its binding to DSS1 (black semicircle) obscures an NES motif. Nuclear transport (green arrow) is presumably directed by NLSs previously identified in the C-terminal region of BRCA2, which are not shown here. Dissociation of BRCA2 from DSS1 may permit nuclear export (blue arrow). (b) The proposed mechanism wherein the nuclear retention of RAD51 (orange circle) is allowed when its binding to the BRC repeats of BRCA2 obscures an NES motif. Nuclear transport (green arrow) of the BRCA2-RAD51 complex is presumably directed by the NLSs in BRCA2. In addition, cytosolic RAD51 may exist in an equilibrium (thin blue arrows) between free monomers and oligomers. Monomeric RAD51 is small enough to diffuse freely across the nuclear membrane (black arrows), whereas oligomers are not. Dissociation of RAD51 from BRCA2 may permit nuclear export (blue arrow). The net result of these different processes is to localize RAD51 predominantly in the nucleus. (c) How the processes shown in a and b may be affected by the BRCA2 D2723H mutation, which prevents DSS1 binding (black X). Mutant BRCA2 is exported from the nucleus (blue arrows), resulting in predominant cytoplasmic localization, and this is proposed to shift the balance toward cytoplasmic localization of RAD51, despite the presence of WT BRCA2. npg a r t i c l e s monomers in which BRC binding obscures the NES, thus promoting nuclear retention.
Depletion of DSS1, which not only binds to BRCA2 but is also a component of the 19S proteasome 42 and RNA-processing complexes 43 , impairs the assembly of RAD51 into foci at sites of DNA damage 44 to mediate DNA HR. This effect has been ascribed previously to a direct function of the BRCA2-DSS1 complex in binding to ssDNA through the formation of oligonucleotide-and oligosaccharide-binding folds 19 , which may not only localize RAD51 to these substrates but also displace the ssDNA-binding protein RPA 10 . Our findings suggest an additional function for DSS1 in HR through regulation of the nuclear localization of BRCA2 and, indirectly, RAD51. In this light, it is notable that mutant forms of BRCA2 in which the DSS1 binding domain has been entirely deleted are still capable of supporting HR [45] [46] [47] . Moreover, DSS1 is apparently required for HR only when the DBD is present 48 . These observations are consistent with our findings: DBD deletion presumably removes the strong NESs that we identified in this work, obviating the necessity for their masking by DSS1 and allowing mutant forms of BRCA2 lacking the DBD to at least partly function in the nucleus even without DSS1.
We surmise that DBD deletion and loss of DSS1 binding in human BRCA2 may lead to subtle defects in HR, which is reminiscent of the phenotypes observed in mutants of the BRCA2 homolog brh2 in the fungus Ustilago maydis that lack dss1 binding 49 . Conversely, the NESs we identified in human BRCA2 are not well conserved in brh2 (Fig. 2a) , raising the possibility that the mechanisms that regulate BRCA2 nuclear localization are not directly comparable between these species. However, U. maydis rad51 contains a conserved NES (Fig. 3a) , suggesting that its localization may depend on the BRC repeat found in brh2, whereas Saccharomyces cerevisiae Rad51 does not (Fig. 3a) , which is consistent with the absence of a Brca2 homolog in yeast.
Several lines of evidence have suggested that the DSS1-masked NES we identified in BRCA2 is dominant in its function over other motifs such as NLSs within the protein that may control nuclear localization 24, 50 . For instance, the BRCA2 D2723H and BRCA2 W2725A point mutants, which both lack DSS1 binding to mask the NES, mislocalize to the cytosol, and the Brca2 D2723H variant is embryonic lethal in mice when homozygous 20 , suggesting that it is nonfunctional. Moreover, our findings suggest that these point mutations probably do not exert their effects simply through BRCA2 destabilization, as their protein expression is not markedly decreased. Instead, they speak to a critical role for the DSS1-BRCA2 interaction in the control of BRCA2-RAD51 localization. These findings raise questions regarding the expected clinical effects of the cancerassociated BRCA2 D2723H allele when expressed in the heterozygous state in germline mutation carriers. Although our findings suggest that BRCA2 D2723H heterozygosity may suffice to mislocalize RAD51, we are unaware that carriers of this mutation exhibit radiosensitivity or other clinical features that are associated with profound defects in DNA repair, which is consistent with the lack of radiosensitivity of cell lines carrying D2723H in vitro (Supplementary Fig. 4c) . However, patients heterozygous for BRCA2 D2723H do appear to be at risk of developing early onset cancers, suggesting that this alteration causes a cumulative rather than an acute effect on genome stability, which acts over years to promote carcinogenesis. Indeed, BRCA2 is often cytoplasmic in cancer cells 24 , and mislocalization of RAD51 has been reported in both familial breast cancer 51 and sporadic cases of prostate cancer 52 .
Notably, our findings also indicate that alterations in the normal intracellular distribution of RAD51 may mark defects in the cellular response to DNA damage arising at several distinct steps (Fig. 6c,d) .
We therefore suggest that quantitative measurement of the nucleocytoplasmic levels of RAD51 may serve as a surrogate marker for these defects, which may be of value in assessments of cancer diagnosis or therapeutic responsiveness.
METHODS
Methods and any associated references are available in the online version of the paper.
To make the mCherry-DSS1 construct, full-length DSS1 sequences were cloned between the BstB1 and BamHI sites, which excised RAD51 from a previously described 54 mCherry-RAD51 vector. The primers used were forward, 5′-GCGTTCGAATATGTCAGAGAAAAAGCAGCCGGTAG-3′; reverse, 5′-CGCGGATCCCTATGAAGTCTCCATCTTATAAC-3′.
To make the sYFP-RAD51 and sYFP-RAD51-SA-ED constructs, full-length sYFP sequences (from pSYFP-C1) were cloned into AgeI and SacI sites, which excised eGFP from eGFP-RAD51 and eGFP-RAD51-SA-ED (previously described in ref. 30 ). The primers used were forward, 5′-ATACCGGTATGGTGAGCAAGGGCGAGGAGCTGTT-3′; reverse, 5′-ATGAGCTCGCTTGTACAGCTCGTCCATGCCGAGAGT-3′.
To make the GST-DBD construct for the in vitro binding assay, the BRCA2 DBD (from hsBRCA2 residues 2461-2975) was PCR amplified from the NLS-sYFP-DBD construct and cloned into the SalI and NotI sites of the vector pGEX-4T3 (GE Healthcare). For GST-DBD D2723H , the same region was PCR amplified from the NLS-sYFP-DBD D2723H construct. The primers used were forward, 5′-GCGTCGACAACTCCAATCAAGCAGCAGCT-3′; reverse, 5′-GCGCGGCCGCTCATACAATACGCAACTTCCACAC-3′.
To make the GST-RAD51 F86E and GST-RAD51-SAM constructs, the respective RAD51 mutant sequences were PCR amplified from the GFP-RAD51 F86E and GFP-RAD51-SAM constructs 30 and cloned into the SalI and NotI sites of the vector pGEX-4T3 using the following primers:
forward, 5′-GCGTCGACATGGCAATGCAGATGCAGCTT-3′; reverse, 5′-GCGCGGCCGCTCAGTCTTTGGCATCTCCCACT-3′.
To make the His-DSS1 construct, full-length DSS1 sequences were cloned into the NdeI and BamHI sites of a modified pET28a vector (Novagen). The primers used were forward, 5′-GCGCCATATGTCAGAGAAAAAGCAGCCG-3′; reverse, 5′-GCGCGGATCCCTATGAAGTCTCCATCTTATAACC-3′. The CRM1 and Ran Q69L constructs for bacterial overexpression were gifts from D. Görlich 33, 55 (Max Planck Institute, Gottingen). BRC4 peptides were synthesized by Cambridge Research Biochemicals Ltd. with an N-terminal biotin moiety attached through a six-aminohexanoic acid spacer and a C-terminal amide. The sequence of the peptide was KEPTLLGFHTASGKKVKIAKESLD KVKNLFDEKEQ.
Cell culture and transfection. 293T and U2OS cells were cultured in sterile filtered growth medium (DMEM with GlutaMAX-1, 4,500 mg l −1 d-glucose, sodium pyruvate and pyridoxine (Gibco) supplemented with 10% fetal calf serum (Gibco) and 2% penicillin-streptomycin (Gibco)) in a 37 °C humidified incubator in the presence of 5% CO 2 . Cells were split every 2-3 d and maintained at 50% confluency. MCF10A cells were grown in DMEM and F12 (1:1) with 15 mM HEPES (Gibco) supplemented with 5% horse serum (Invitrogen), 10 µg ml −1 insulin (Sigma), 20 ng ml −1 epidermal growth factor (Sigma), 100 ng ml −1 cholera toxin (Sigma), 500 ng ml −1 hydrocortisone (Sigma) and 1% penicillin-streptomycin. ES cells were grown in gelatinized plates with Glasgow minimum essential medium (Sigma) supplemented with 15% FBS (Hyclone), 1 mM sodium pyruvate, 1× nonessential amino acids (Invitrogen), 1× glutamate-penicillin-streptomycin, (Invitrogen), 100 µM β-mercaptoethanol and 1,000 units per ml of leukemia inhibitory factor (ESGRO Chemicon).
Transient transfection of DBD plasmids was performed by lipofection using Lipofectamine 2000 (Invitrogen) using 1 µg DNA and 3 µl Lipofectamine in OptiMEM (Invitrogen) for 10 6 cells. For high-content microscopy, U2OS cells were plated in a 24-well plate. 1 d after plating, cells were transfected with a NLS-sYFP-DBD construct (either WT or the D2723H mutant; 0.25 µg) together with an empty mCherry plasmid or an mCherry-DSS1 plasmid (0.125 µg) using Lipofectamine. Full-length BRCA2 was introduced into U2OS cells using the Amaxa Cell Line Nucleofector Kit V and the Nucleofector I device with the program X-01 (Lonza). For high-content microscopy experiments, MCF10A cells were reverse transfected with the indicated siRNAs at a final concentration of 25 nM using Dharmafect I transfection reagent (Fermentas GmbH, Thermo Fisher Scientific) in a 96-well plate. EUFA423BRCA2 (EUFA-BRCA2#34) cell lines were established by stably transfecting EUFA423 cells (SV40-immortalized BRCA2-deficient human fibroblasts) with the pCAG-Flag-BRCA2-IRES-Neo construct in standard DMEM plus 10% FBS with penicillin-streptomycin supplemented with 750 µg ml −1 G418.
Cell viability assay. Cells were plated into 96-well plates at a density of 8,000 cells per well. Different doses of MMC (Sigma) were added (four wells per dose per cell line), and the plates were incubated at 37 °C for five doubling times. CellTiter-Blue reagents (Promega) were added to each well of the 96-well plate according to the manufacturer's guidelines. The plates were incubated at 37 °C for ~1-2 h in a humidified 5% CO 2 atmosphere. The number of viable cells was determined using the Fusion plate reader at an absorbance of 590 nm. A similar procedure was followed for the cell viability assay for ES cells exposed to different doses of ionizing radiation using a Faxitron X-ray unit.
Lifetime measurements. DBD-and DSS1-transfected cells were plated on MatTek poly-D-lysine-coated, number 1 glass-bottomed 35-mm dishes, and the medium was replaced with phenol red-free L15. Experiments were performed on a TCSPC system (Becker and Hickl Inc., SPC 830) connected to the descanned and fiber-coupled output of an Olympus FV300 confocal scanner (Laser Analytics Group, Department of Chemical Engineering). A supercontinuum laser (Fianium Inc., SC400) was used as the illumination source. An excitation wavelength of 436 ± 1 nm (range) was selected by an Acousto Optic Tunable Filter (AOTFnC VIS, AA Opto-Electronique, Orsay, France) and coupled into the confocal scanner. The fluorescence output was filtered between 480 and 550 nm before being detected by the TCSPC photomultiplier tube. TCSPC data were analyzed to generate lifetime information on dedicated Matlab (MathWorks, Inc.) and Becker and Hickl software.
Immunofluorescence analyses. Cell staining and immunofluorescence analyses were carried out as described previously 56 . Briefly, transfected and untransfected cells were grown on coverslips and subjected to different treatments as indicated in the text before fixation. Cells for IF experiments were grown on coverslips to 70-80% confluence, washed in PBS and fixed in 4% paraformaldehyde or 95% ethanol plus 5% acetic acid. The cells were permeabilized by adding Trisbuffered saline (TBS) with 0.1% Triton X-100 and 0.2% Tween (TBS-TritonTween) for 5 min, blocked in TBS-Triton-Tween plus 2% BSA and incubated with the indicated primary and secondary antibodies (Table 1) in a humidified chamber with TBS-Tween-Triton washes between the primary and secondary incubation. The coverslip was then mounted onto a slide for viewing using a mounting medium with DAPI. Immunofluorescence images were captured using a Zeiss Axiovert200 LSM510meta confocal microscope using a 40× objective with fixed optical slice, laser power and detector and amplifier settings for all samples across each individual experiment to allow for comparison.
High-content microscopy for adherent cells. High-content microscopy experiments were performed on the Cellomics VTI-Arrayscan Instrument (Thermo Fisher), as described previously 56 , in 96-well (Nunc) or 24-well plates. Transfections were performed using 0.25 µg or 0.125 µg of DNA and Lipofectamine. The cells were treated with specified DNA-damaging agents, fixed with 4% formaldehyde for 10 min, immunostained as per conventional protocols and incubated with 0.1% Triton X-100 with Hoechst 33342 DNA dye for 10 min followed by PBS washes. Cellomics VTI ArrayScan was used for image acquisition using the Compartmental Analysis BioApplication and a 40× nonimmersion objective. Hoechst staining was used for object identification, and the average intensity of the fluorescent signal per nucleus was estimated using the targetactivation Cellomics BioApplication. 300-500 cells were analyzed per well, and standard errors were calculated from an average of the means of multiple wells.
Immunoprecipitation. Whole-cell extracts were prepared from 15 × 10 6 293T cells 24 h after transfection. The trypsinized or scraped cells were spun down in a Beckman centrifuge at 1,000 r.p.m. for 3 min, washed once with PBS and resuspended in 1 ml of ice-cold immunoprecipitation lysis buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 0.5% NP-40, 10 mM EDTA, 2 mM β-glycerophosphate, 1 mM DTT and 1 mM PMSF supplemented with protease inhibitors (Roche)) for 15 min on ice. Extracts were then spun down in an Eppendorf centrifuge for 15 min at 12,000 r.p.m., and the supernatant was collected and quantified for protein concentration by the bicinchoninic acid assay (Sigma). 1 mg of wholecell extract was precleared with 30 µl of a 50% slurry of protein A-Sepharose (Sigma) for 20 min at 4 °C with gentle shaking to reduce nonspecific proteinbead interactions followed by immunoprecipitation using 1-2 µg of antibody npg (specified in Table 1 ) and 30 µl of a 50% slurry of protein A-Sepharose overnight in a cold room with gentle shaking. The immune complexes were then washed four times in ice-cold immunoprecipitation lysis buffer and one time in PBS before resuspension in 4× loading buffer (Invitrogen) and 50 mM DTT.
In vitro pulldown assays. The in vitro CRM1 binding assays were performed using an assay described previously 33 . For each assay condition, 1 µg of GSTtagged protein (DBD, DBD D2723H , RAD51 F86E or RAD51-SAM) bound to glutathione-Sepharose 4B beads was incubated with 1 µM CRM1 and/or Ran-GTP, as indicated, for 1 h at 4 °C in 500 µl of binding buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 25 mM KCl, 50 mM LiCl, 2 mM Mg(OAc) 2 , 5 mM DTT and 20 µM GTP-γS (a nonhydrolyzable GTP analog)). DSS1 proteins or BRC4 peptides (or binding buffer alone for the GST control) were then added to individual tubes as indicated, followed by incubation at 4 °C for 2 h. Beads were washed three times with 500 µl of binding buffer, followed by elution of proteins and SDS-PAGE. DBD, DBD D2723H , RAD51 F86E and RAD51-SAM were detected by immunoblotting with antibody to GST ( Table 1) , and CRM1 was detected by immunoblotting with His-specific antibody ( Table 1) .
Cell fractionation. Cells were washed in PBS and resuspended in solution A (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.34 M sucrose, 10% glycerol, 1 mM DTT, protease and phosphatase inhibitors). Cells were incubated on ice for 5 min, and the cytoplasmic (S1) and nuclear (P1) fractions were harvested by centrifugation at 1,300g for 4 min. Isolated nuclei were then washed in solution A, lysed in solution B (0.1% Triton X-100, 3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, protease and phosphatase inhibitors) and incubated on ice for 10 min. The soluble nuclear (S3) and chromatin fractions were harvested by centrifugation at 1,700g for 4 min. To release chromatin-bound proteins by nuclease treatment, the P2 fraction was incubated in solution A plus 1 mM CaCl 2 and 5 U micrococcal nuclease for 15 min at 37 °C, after which the reaction was stopped by the addition of 1 mM EGTA and spun down at 10,000g to collect the supernatant enriched for chromatin proteins (P3). The S3 and P3 fractions were pooled to obtain a nuclear extract.
Proteins were resolved on 3-8% Tris-acetate SDS-PAGE (Invitrogen) for the BRCA2 experiments, 4-12% MES SDS-PAGE (Invitrogen) for most of the other experiments and 4-20% Tris-glycine gels for the DSS1 experiments. Transfer was performed to PVDF membranes (Immobilon-P, Millipore) at 30 V for 2 h. Western blots were blocked in 5% milk (Marvel) and 0.5% Tween-20 in TBS for 30 min at room temperature before probing with the appropriate primary antibodies ( Table 1) . Western blots were developed with horseradish peroxidase-conjugated secondary antibodies against rabbit and mouse at 1/1,5000 and 1/1,0000, respectively, and detected with either enhanced chemiluminescence (ECL) or ECL Plus detection reagents (Amersham) and exposed to CL-Xposure Film (Pierce).
Quantitative RT-PCR.
To analyze the effects of siRNA knockdown, 0.5 µg of total RNA, which was extracted with the RNeasy Plus Mini Kit (Qiagen), was used for cDNA synthesis using the Cloned AMV First-Strand Synthesis kit (Invitrogen). Quantitative RT-PCR was performed using the LightCycler 480 SYBR Green I Master mix (Roche) with the following primers:
GAPDH forward, TGAGCTTGACAAAGTGGTCG; reverse, GTCAGTGGT GGACCTGACCT; CHK1 forward, CCAGATGCTCAGAGATTCTTCCA; reverse, TGTTCA ACAAACGCTCACGATTA; ATM forward, GGCTATTCAGTGTGCGAGACA; reverse, TGGCTCC TTTCGGATGATGGA;
ATR forward, TCCCTTGAATACAGTGGCCTA; reverse, TCCTTGA AAGTACGGCAGTTC; DSS1 forward, GAAAAAGCAGCCGGTAGACTT; reverse, ATCCCAAT TATCCTCCCAGACA; BRCA2 forward, TTGGCTGATGGTGGATGGCTCATA; reverse, TTTGGA TCCACACCTGGAGTGTCA.
The cycle threshold (Ct) values were obtained from the LightCycler 480 and referenced to the expression of the housekeeping gene, GAPDH. All samples were then normalized to the non-Targeting siRNA pool (Fermentas GmbH).
For the RT-PCR comparison between mmBrca2 and hsBRCA2, the following primers were used: mouse GAPDH forward, GAAGGTCGGTGTGAACGGATTT; reverse, CATTTGATGTTAGTGGGGTCTC;
Brca2 5022F, TTATGCAGGAATCTTTGGACA; 5173R, AGTTCTGC ATTTCTTCACATTTT; BRCA2 731F, AAAGTTTGTGAAGGGTCGTC; 840R, TAAGGGTGGG TGGTGTAGC.
RNA was made from exponentially growing ES cells using a Qiagen total RNA kit. 2 µg RNA was converted into cDNA using the Roche Transcriptor High Fidelity cDNA Synthesis Kit, and quantitative RT-PCR was performed as described above. The Ct values were directly represented in the figure to provide an unbiased assessment, and GAPDH was used as a control.
The original images of the blots presented in this study are shown in Supplementary Figure 8 
